<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892810</url>
  </required_header>
  <id_info>
    <org_study_id>Grenoble University Hospital</org_study_id>
    <nct_id>NCT04892810</nct_id>
  </id_info>
  <brief_title>Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma</brief_title>
  <acronym>PAIÂ²HCC</acronym>
  <official_title>Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <brief_summary>
    <textblock>
      This cohort study compares immune response induced in two groups of small HCC patients&#xD;
      treated by ablation (group1 RFA, group 2 MWA). Patients will benefit for tumoral and non&#xD;
      tumoral biopsies prior to treatment and stepped peripheral blood samples juste before&#xD;
      ablation and during the first month after.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To compare induced immunomodulation by RFA and MWA in HCC patients</measure>
    <time_frame>one month</time_frame>
    <description>Comparison of modulation of immune cells (frequency, activity, function) between the two groups. Study of immune cells will include T cells with immune checkpoints molecules (PD-1+ CD8+ T, 4-1BB+ CD8+ T, LAG-3+ CD8+ T, Tim-3+ CD8+ T, COS+ CD8+ T) before and after the treatment (day 0, day 2, day 7, day 30)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate early induced immunomodulation after RFA in HCC patients</measure>
    <time_frame>one month</time_frame>
    <description>Differences of frequencies, activities, functions of immune cells before and after the RFA treatment (day 0, day 2, day 7, day 30). Study of immune cells will include T cells with immune checkpoints molecules (PD-1+ CD8+ T, 4-1BB+ CD8+ T, LAG-3+ CD8+ T, Tim-3+ CD8+ T, COS+ CD8+ T)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate early induced immunomodulation after MWA in HCC patients</measure>
    <time_frame>one month</time_frame>
    <description>Differences of frequencies, activities, functions of immune cells before and after the MWA treatment (day 0, day 2, day 7, day 30). Study of immune cells will include T cells with immune checkpoints molecules (PD-1+ CD8+ T, 4-1BB+ CD8+ T, LAG-3+ CD8+ T, Tim-3+ CD8+ T, COS+ CD8+ T)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <description>Patient with HCC and decision of treatment with ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MWA</arm_group_label>
    <description>Patient with HCC and decision of treatment with ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous ablation</intervention_name>
    <description>Hepatic Percutaneous Ablation with radiofrequency or microwave</description>
    <arm_group_label>MWA</arm_group_label>
    <arm_group_label>RFA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 40 years old that can benefit for ablation (either RFA or MWA) for HCC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven HCC for less than 3 months before ablation&#xD;
&#xD;
          -  Decision of ablation treatment in multidisciplinary meeting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fibrolamellar HCC&#xD;
&#xD;
          -  Hepatocholangiocarcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Julien GUELFI, PH</last_name>
    <phone>04 76 76 89 09</phone>
    <email>JGhelfi@chu-grenoble.fr</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

